Bieżący numer
Archiwum
Online first
O czasopiśmie
Redakcja
Rada Naukowa
Wydawca
Standardy etyczne i procedury
Bazy indeksacyjne
Recenzenci
Recenzenci Honorowi
Prenumerata
Kontakt
Najczęściej czytane artykuły
Dla autorów
Opłata za przetwarzanie artykułu (APC)
Książki i Konferencje
Książki
Konferencje
SARS CoV-2/COVID-19
PRACA ORYGINALNA
Symptoms of autonomic dysfunction in systemic sclerosis assessed with the COMPASS-31 questionnaire: associations with disease severity and chronic pain
1
Department of Clinical Rheumatology, Institute of Rheumatology, School of Medicine, University of Belgrade, Serbia
2
Department of Clinical Rheumatology, Institute of Rheumatology, Belgrade, Serbia
Data nadesłania: 14-12-2025
Data ostatniej rewizji: 04-02-2026
Data akceptacji: 24-02-2026
Data publikacji online: 23-10-2026
Autor do korespondencji
Predrag Ostojic
Department of Clinical Rheumatology, Institute of Rheumatology, School of Medicine, University of Belgrade, Serbia
Department of Clinical Rheumatology, Institute of Rheumatology, School of Medicine, University of Belgrade, Serbia
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Introduction:
Autonomic dysfunction in systemic sclerosis (SSc) mainly influences the cardiovascular system and gastrointestinal motility. Observations to date indicate that it is not a rare complication of SSc. The Composite Autonomic Symptom Score (COMPASS-31) questionnaire assesses the impact of autonomic dysfunction on the quality of life of patients and the dependence on the involvement of specific systems. This study aimed to assess the prevalence and severity of symptoms of autonomic dysfunction in patients with SSc, as well as the relationship between these symptoms and other clinical manifestations of the disease.
Material and methods:
Fifty-five consecutive patients with SSc were included in this study. All patients completed the COMPASS-31 questionnaire, which consists of 31 items, quantifying 6 autonomic domains: orthostatic intolerance (OI), vasomotor dysfunction (VD), secretomotor dysfunction (SD), gastrointestinal dysfunction (GD), urinary bladder dysfunction (BD) and pupillomotor dysfunction (PD). Differences in the total COMPASS-31 score and domain-specific scores were assessed with respect to disease subset, SSc-specific antibodies, capillaroscopic findings, lung diffusing capacity and chronic pain. Furthermore, we assessed the correlation between the COMPASS-31 score and disease status (assessed using the Scleroderma Assessment Questionnaire), and the severity of gastrointestinal (GI) symptoms (assessed using the the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 questionnaire).
Results:
Symptoms of OI were found in 32/55 (58.2%), VD in 49/55 (89.1%), SD in 36/55 (65.5%), GD in 40/55 (72.7%), BD in 26/55 (47.3%) and PD in 30/55 (54.5%) of our patients with SSc. The total COMPASS-31 score did not correlate with age or disease duration. Prevalence of symptoms of different autonomic dysfunctions was similar regardless of disease subtype, antibodies or capillaroscopic findings. Patients with decreased lung diffusing capacity had more frequent and more severe symptoms of GD and BD, and a higher PD score. Patients with chronic pain had more frequent symptoms of OI, SD, GD, BD and PD, than patients without pain. However, prevalence of different autonomic dysfunctions was similar in patients with nociceptive, neuropathic, or mixed pain. We found that patients with more severe disease, including GI involvement, had more common symptoms of autonomic dysfunction.
Conclusions:
Patients with more severe disease, as well as patients suffering from chronic pain, reported more severe symptoms of autonomic dysfunction.
Autonomic dysfunction in systemic sclerosis (SSc) mainly influences the cardiovascular system and gastrointestinal motility. Observations to date indicate that it is not a rare complication of SSc. The Composite Autonomic Symptom Score (COMPASS-31) questionnaire assesses the impact of autonomic dysfunction on the quality of life of patients and the dependence on the involvement of specific systems. This study aimed to assess the prevalence and severity of symptoms of autonomic dysfunction in patients with SSc, as well as the relationship between these symptoms and other clinical manifestations of the disease.
Material and methods:
Fifty-five consecutive patients with SSc were included in this study. All patients completed the COMPASS-31 questionnaire, which consists of 31 items, quantifying 6 autonomic domains: orthostatic intolerance (OI), vasomotor dysfunction (VD), secretomotor dysfunction (SD), gastrointestinal dysfunction (GD), urinary bladder dysfunction (BD) and pupillomotor dysfunction (PD). Differences in the total COMPASS-31 score and domain-specific scores were assessed with respect to disease subset, SSc-specific antibodies, capillaroscopic findings, lung diffusing capacity and chronic pain. Furthermore, we assessed the correlation between the COMPASS-31 score and disease status (assessed using the Scleroderma Assessment Questionnaire), and the severity of gastrointestinal (GI) symptoms (assessed using the the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 questionnaire).
Results:
Symptoms of OI were found in 32/55 (58.2%), VD in 49/55 (89.1%), SD in 36/55 (65.5%), GD in 40/55 (72.7%), BD in 26/55 (47.3%) and PD in 30/55 (54.5%) of our patients with SSc. The total COMPASS-31 score did not correlate with age or disease duration. Prevalence of symptoms of different autonomic dysfunctions was similar regardless of disease subtype, antibodies or capillaroscopic findings. Patients with decreased lung diffusing capacity had more frequent and more severe symptoms of GD and BD, and a higher PD score. Patients with chronic pain had more frequent symptoms of OI, SD, GD, BD and PD, than patients without pain. However, prevalence of different autonomic dysfunctions was similar in patients with nociceptive, neuropathic, or mixed pain. We found that patients with more severe disease, including GI involvement, had more common symptoms of autonomic dysfunction.
Conclusions:
Patients with more severe disease, as well as patients suffering from chronic pain, reported more severe symptoms of autonomic dysfunction.
REFERENCJE (65)
1.
Bairkdar M, Rossides M, Westerlind H, et al. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford) 2021; 60: 3121–3133, DOI: 10.1093/rheumatology/keab190.
2.
Knupp-Oliveira S, Cerinic MM. Polyneuropathy as initial manifestation of systemic sclerosis (scleroderma). Scand J Rheumatol 1999; 28: 260–261, DOI: 10.1080/03009749950155661.
3.
Hietaharju A, Jääskeläinen S, Kalimo H, Hietarinta M. Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). Muscle Nerve 1993; 16: 1204–1212, DOI: 10.1002/mus.880161110.
4.
Yagci I, Kenis-Coskun O, Ozsoy T, et al. Increased stiffness of median nerve in systemic sclerosis. BMC Musculoskelet Disord 2017; 18: 434, DOI: 10.1186/s12891-017-1793-9.
5.
Adler BL, Russell JW, Hummers LK, et al. Symptoms of autonomic dysfunction in systemic sclerosis assessed by the COMPASS-31 questionnaire. J Rheumatol 2018; 45: 1145–1152, DOI: 10.3899/jrheum.170868.
6.
Koszewicz M, Gosk-Bierska I, Bilińska M, et al. Autonomic dysfunction in primary Raynaud’s phenomenon. Int Angiol 2009; 28: 127–131.
7.
Pancera P, Sansone S, Presciuttini B, et al. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud’s phenomenon. Clin Sci (Lond) 1999; 96: 49–57.
8.
Zimba O, Gasparyan AY. Designing, conducting, and reporting survey studies: a primer for researchers. J Korean Med Sci 2023; 38: e403, DOI: 10.3346/jkms.2023.38.e403.
9.
Sletten DM, Suarez GA, Low PA, et al. COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc 2012; 87: 1196–1201, DOI: 10.1016/j.mayocp. 2012.10.013.
10.
Drulović J, Gavrilović A, Crnošija L, et al. Validation and cross- cultural adaptation of the COMPASS-31 in Croatian and Serbian patients with multiple sclerosis. Croat Med J 2017; 58: 342–348, DOI: 10.3325/cmj.2017.58.
11.
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–590, DOI: 10.1002/art.1780230510.
12.
Le Roy EC, Black C, Fleischmajer, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–205.
13.
Freynhagen R, Baron R, Gockel U, Tölle TR. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22: 1911–1920, DOI: 10.1185/030079906X132488.
14.
Ostojic P, Damjanov N. The scleroderma assessment questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol 2006; 65: 168–175, DOI: 10.1007/s00393-005- 0006-3.
15.
Zekovic A, Damjanov N. Validation of Serbian version of UCLA scleroderma clinical trial consortium gastrointestinal tract instrument in 104 patients with systemic sclerosis. Rheumatol Int 2017; 37: 735–741, DOI: 10.1007/s00296-017-3680-y.
16.
Bertinotti L, Bracci S, Nacci F, et al. The autonomic nervous system in systemic sclerosis: a review. Clin Rheumatol 2004; 23: 1–5, DOI: 10.1007/s10067-003-0812-4.
17.
Cozzolino D, Naclerio C, Iengo R, et al. Cardiac autonomic dysfunction precedes the development of fibrosis in patients with systemic sclerosis. Rheumatology (Oxford) 2002; 41: 586–588, DOI: 10.1093/rheumatology/41.5.586.
18.
Stewart JM. Common syndromes of orthostatic intolerance. Pediatrics 2013; 131: 968–980, DOI: 10.1542/peds.2012-2610.
19.
Bienias P, Ciurzyński M, Glińska-Wielochowska M. Heart rate turbulence assessment in systemic sclerosis: the role for the detection of cardiac autonomic nervous system dysfunction. Rheumatology (Oxford) 2010; 49: 355–360, DOI: 10.1093/ rheumatology/kep394.
20.
Di Battista M, Wasson CW, Alcacer-Pitarch B, Del Galdo F. Autonomic dysfunction in systemic sclerosis: a scoping review. Semin Arthritis Rheum 2023; 63: 152268, DOI: 10.1016/ j.semarthrit.2023.152268.
21.
Othman KM, Assaf NY, Farouk HM, Hassan IMA. Autonomic dysfunction predicts early cardiac affection in patients with systemic sclerosis. Clin Med Insights Arthritis Musculoskelet Disord 2010; 3: 43–54, DOI: 10.4137/cmamd.s4940.
22.
Bellocchi C, Carandina A, Montinaro B, et al. The interplay between autonomic nervous system and inflammation across systemic autoimmune diseases. Int J Mol Sci 2022; 23: 2449, DOI: 10.3390/ijms23052449.
23.
Ferri C, Emdin M, Giuggioli D, et al. Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis. Br J Rheumatol. 1997; 36: 669–676, DOI: 10.1093/rheumatology/36.6.669.
24.
Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology 2005; 44: 587–596, DOI: 10.1093/rheumatology/keh552.
25.
Masini F, Galiero R, Pafundi PC, et al. Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients. J Scleroderma Relat Disord 2021; 6: 256–263, DOI: 10.1177/23971983211020617.
26.
Ismail AMA, El Gressy NSSA, Hegazy MD, et al. Effects of diaphragmatic breathing exercise on sleeping quality, cortisol, cardiovascular autonomic functions, depression, and fatigue: a randomized-controlled trial in women with systemic sclerosis. Reumatologia 2025; 63: 89–96, DOI: 10.5114/reum/200193.
27.
Giuliano F, Rampin O. Neural control of erection. Physiol Behav 2004; 83: 189–201, DOI: 10.1016/j.physbeh.2004.08.014.
28.
Foocharoen C, Tyndall A, Hachulla E, et al. Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. Arthritis Res Ther 2012; 14: R37, DOI: 10.1186/ ar3748.
29.
Gao R, Qing P, Sun X, et al. Prevalence of sexual dysfunction in people with systemic sclerosis and the associated risk factors: a systematic review. Sex Med 2021; 9: 100392, DOI: 10.1016/ j.esxm.2021.100392.
30.
Jaeger VK, Walker UA. Erectile dysfunction in systemic sclerosis. Curr Rheumatol Rep 2016; 18: 49, DOI: 10.1007/s11926-016- 0597-5.
31.
Ismail AMA, Hamed DE. Erectile dysfunction and metabolic syndrome components in obese men with psoriasis: response to a 12-week randomized controlled lifestyle modification program (exercise with diet restriction). Ir J Med Sci 2024; 193: 523–529, DOI: 10.1007/s11845-023-03412-8.
32.
Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485–494, DOI: 10.1093/qjmed/hcm052.
33.
Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008: 67: 110–116, DOI: 10.1136/ard.2006.066985.
34.
Denton CP. Renal manifestations of systemic sclerosis – clinical features and outcome assessments. Rheumatology 2008; 47(Suppl 5): v54–v56, DOI: 10.1093/rheumatology/ken307.
35.
Gibney EM, Parikh CR, Jani A, et al. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant 2004; 4: 2027–2031, DOI: 10.1111/j.1600-6143.2004.00605.x.
36.
International Dry Eye WorkShop Study Group. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 93–107, DOI: 10.1016/s1542-0124(12)70082-4.
37.
Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens 2014; 40: 248–256, DOI: 10.1097/ICL.0000000000000042.
38.
Mayali H, Erdogan M, Altinisik M, et al. Analysis of tear osmolarity, stability and productionin systemic sclerosis. Eur Eye Res 2021; 1: 150–155, DOI: 10.14744/eer.2021.63935.
39.
Gagliano C, Visalli E, Toro MD, et al. Dry eye in systemic sclerosis patients: novel methods to monitor disease activity. Diagnostics (Basel) 2020; 10: 404, DOI: 10.3390/diagnostics 10060404.
40.
Szucs G, Szekanecz Z, Aszalos Z, et al. A wide spectrum of ocular manifestations signify patients with systemic sclerosis. Ocul Immunol Inflamm 2021; 29: 81–89, DOI: 10.1080/ 09273948.2019.1657467.
41.
Mancel E, Janin A, Gosset D, et al. Conjunctival biopsy in scleroderma and primary Sjögren’s syndrome. Am J Ophthalmol 1993; 115: 792–799, DOI: 10.1016/s0002-9394(14) 73650-5.
42.
Lee KA, Choi W, Kim J, Kim HS. High prevalence of salivary gland ultrasound abnormalities in systemic sclerosis. Joint Bone Spine 2021; 88: 105113, DOI: 10.1016/j.jbspin.2020.105113.
43.
Janin A, Gosselin B, Gosset D, et al. Histological criteria of Sjögren’s syndrome in scleroderma. Clin Exp Rheumatol 1989; 7: 167–169.
44.
Avouac J, Sordet C, Depinay C, et al. Systemic sclerosis- associated Sjögren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006; 54: 2243–2249, DOI: 10.1002/art.21922.
45.
Garrett JR. The proper role of nerves in salivary secretion: a review. J Dent Res 1987; 66: 387–397, DOI: 10.1177/ 00220345870660020201.
46.
Hughes M, Harrison E, Herrick AL, et al. An evaluation of autonomic and gastrointestinal symptoms, and gastric emptying, in patients with systemic sclerosis. J Scleroderma Relat Disord 2024; 10: 42–49, DOI: 10.1177/23971983241288039.
47.
Denaxas K, Ladas SD, Karamanolis GP. Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol 2018; 31: 165–170, DOI: 10.20524/aog.2018.0228.
48.
Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48(Suppl 3): iii36–iii39, DOI: 10.1093/ rheumatology/ken485.
49.
Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 1995, 40: 1892–1901, DOI: 10.1007/BF02208652.
50.
Polkowska-Pruszyńska B, Gerkowicz A, Szczepanik-Kułak P, Krasowska D. Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature. Arch Dermatol Res 2019; 311: 1–8, DOI: 10.1007/s00403-018-1874-0.
51.
Sattar B, Chokshi RV. Colonic and anorectal manifestations of systemic sclerosis. Curr Gastroenterol Rep 2019; 21: 33, DOI: 10.1007/s11894-019-0699-0.
52.
Nakane S, Umeda M, Kawashiri SY, et al. Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies. Arthritis Res Ther 2020; 22: 32, DOI: 10.1186/s13075-020-2128-z.
53.
Kumar S, Singh J, Kedika R, et al. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. Am J Physiol Gastrointest Liver Physiol 2016; 310: G1052–G1060, DOI: 10.1152/ajpgi.00034.2016.
54.
Pacini G, Paolino S, Trombetta AC, et al. Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. Rheumatology 2020; 59: 1315–1324, DOI: 10.1093/rheumatology/kez438.
55.
Minervini R, Morelli G, Minervini A, et al. Bladder involvement in systemic sclerosis: urodynamic and histological evaluation in 23 patients. Eur Urol 1998; 34: 47–52, DOI: 10.1159/000019678.
56.
John G. Systemic sclerosis and urinary symptoms: a complex pathophysiology. Clin Rheumatol 2000; 39: 5–8, DOI: 10.1007/s10067-019-04714-y.
57.
Faddan AA, Hassanien M, Talaat EA, Gadelkareem RA. Do the incidence and severity of lower urinary tract symptoms measured by the International Consultation on Incontinence Questionnaires correlate with urodynamic findings in patients with systemic sclerosis? Curr Urol 2025; 19: 274–279, DOI: 10.1097/CU9.0000000000000208.
58.
Ferrari G, Marques J, Gandhi R, et al. Using dynamic pupillometry as a simple screening tool to detect autonomic neuropathy in patients with diabetes: a pilot study. Biomed Eng Online 2010; 9: 26, DOI: 10.1186/1475-925X-9-26.
59.
De Seze J, Arndt C, Stojkovic T, et al. Pupillary disturbances in multiple sclerosis: correlation with MRI findings. J Neurol Sci 2001; 188: 37–41, DOI: 10.1016/s0022-510x(01)00540-8.
60.
Giza E, Fotiou D, Bostantjopoulou S, et al. Pupil light reflex in Parkinson’s disease: evaluation withpupillometry. Int J Neurosci 2011; 121: 37–43, DOI: 10.3109/00207454.2010.526730.
61.
Aydogmus Y, Uzun S, Gundogan FC, et al. Is overactive bladder a nervous or bladder disorder? Autonomic imaging in patients with overactive bladder via dynamic pupillometry. World J Urol 2017; 35: 467–472, DOI: 10.1007/s00345-016-1880-9.
62.
Chougule PS, Najjar RP, Finkelstein MT, et al. Light-induced pupillary responses in Alzheimer’s disease. Front Neurol 2019; 10: 360, DOI: 10.3389/fneur.2019.00360.
63.
Richardson C, Agrawal R, Lee J, et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin Arthritis Rheum 2016; 46: 109–114, DOI: 10.1016/ j.semarthrit.2016.02.004.
64.
Volkmann ER, Tashkin DP, Leng M, et al. Association of symptoms of gastroesophageal reflux, esophageal dilation, and progression of systemic sclerosis-related interstitial lung disease. Arthritis Care Res 2023; 75: 1690–1697, DOI: 10.1002/acr.25070.
65.
Posavec AL, Šalamon L, Huzjan Korunić R, et al. Esophageal diameter on high-resolution computed tomography – a potential useful marker for interstitial lung disease severity in patients with systemic sclerosis. Acta Clin Croat 2024; 63: 693–700, DOI: 10.20471/acc.2024.63.03-04.30.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
ARTYKUŁ POWIĄZANY
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
Przetwarzamy dane osobowe zbierane podczas odwiedzania serwisu. Realizacja funkcji pozyskiwania informacji o użytkownikach i ich zachowaniu odbywa się poprzez dobrowolnie wprowadzone w formularzach informacje oraz zapisywanie w urządzeniach końcowych plików cookies (tzw. ciasteczka). Dane, w tym pliki cookies, wykorzystywane są w celu realizacji usług, zapewnienia wygodnego korzystania ze strony oraz w celu monitorowania ruchu zgodnie z Polityką prywatności. Dane są także zbierane i przetwarzane przez narzędzie Google Analytics (więcej).
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
